Immunovant’s IMVT-1402 Shows Strong Early Results in Hard-to-Treat Rheumatoid Arthritis, Driving Stock Surge

Immunovant, Inc. presented 16-week open-label data for IMVT-1402 in 170 patients with difficult-to-treat rheumatoid arthritis; 165 completed evaluation. All participants had previously failed at least two advanced therapies, such as JAK inhibitors and anti-TNF biologics. At a 600 mg weekly subcutaneous dose, 72.7 % achieved ACR20, 54.5 % ACR50 and 35.8 % ACR70. In the subgroup that had failed both a JAK inhibitor and an anti-TNF agent, response rates were 72.0 % ACR20, 53.3 % ACR50 and 37.4 % ACR70. No new safety signals were identified, and investigators described the drug as safe and well-tolerated.

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVTImmunovant (IMVT) Stock Jumps 22% After Impressive Rheumatoid Arthritis Drug DataImmunovant (IMVT) Stock Surges 22% on Positive Rheumatoid Arthritis Trial Data

The readout arrived with Immunovant’s fiscal Q4 reporting a $147.9 million net loss ($0.73 per share), missing consensus of $0.59–$0.60. R&D spending rose to $142.3 million, reflecting $39 million tied to batoclimab’s discontinuation. The company held $902.1 million in cash, which it said is sufficient to fund a launch of IMVT-1402 in Graves’ disease. Pre-market trading showed a roughly 22 % gain; intraday data later recorded a 35 % increase, making IMVT a leading health-care mover.

Immunovant Shares Just Surged 35% – Here’s Why

Immunovant confirmed full enrollment in the cutaneous lupus erythematosus proof-of-concept study, with topline data expected in the second half of 2026. The company maintains registrational timelines for Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, targeting pivotal readouts in 2027. Roivant Sciences, the majority owner, described the Graves’ disease program as a near-term catalyst. Immunovant said the trial showed “no new drug-related safety signals” and that its cash position “provides adequate runway to support commercial launch in Graves’ disease.”

Immunovant (IMVT) Stock Surges 22% on Positive Rheumatoid Arthritis Trial DataImmunovant Shares Just Surged 35% – Here’s WhyImmunovant (IMVT) Stock Jumps 22% After Impressive Rheumatoid Arthritis Drug Data

Analysts flagged the open-label design as a limitation, noting that the absence of a blinded, placebo-controlled comparator could affect efficacy interpretation. Roivant’s risk warning underscored uncertainty that later trial phases may not replicate the early signal. Sources also differ on the magnitude of the stock move, citing a 22 % pre-market rise versus a 35 % intraday surge.

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

• “highly compelling” — David Risinger, Analyst, Leerink Partners

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

• “potential to become a blockbuster,” — David Risinger, Analyst, Leerink Partners

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

• “exciting potential for a new, differentiated mechanism” — Matt Gline, CEO, Roivant Sciences

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

• “Roivant also warned that product-candidate potential, trial timing, approvals and commercial outcomes remain forward-looking and subject to risks, including later trials not matching early results.” — Roivant Sciences

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Topline data from the cutaneous lupus erythematosus study are expected in late 2026; rheumatoid arthritis updates are slated for the second half of 2026; and pivotal trials in Graves’ disease and myasthenia gravis are projected for 2027.

Immunovant Shares Just Surged 35% – Here’s WhyImmunovant (IMVT) Stock Surges 22% on Positive Rheumatoid Arthritis Trial DataImmunovant (IMVT) Stock Jumps 22% After Impressive Rheumatoid Arthritis Drug Data